Atherosclerosis in 2012: What is new?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 4, 2012, Pages 170-173

  Jawień, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Atherosclerosis; Hemostatic system; Translational medicine

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CANAKINUMAB; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; THROMBIN;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; DISEASE COURSE; HEMOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 84860717962     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Jawień J. New insights into immunological aspects of atherosclerosis. Pol Arch Med Wewn. 2008; 118: 127-131.
2. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; 364: 1746-1760.
3. Massberg S, Brand K, Grüner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196: 887-896.
4. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005; 96: 612-616. (Pubitemid 40478327)
5. Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol. 2008; 28: 1920-1927.
6. Borissoff JI, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010; 122: 821-830.
7. Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-C beta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation. 2009; 120: 774-784.
8. With Notø AT, Mathiesen EB, Østerud B, et al. Increased thrombin generation in persons with echogenic carotid plaques. Thromb Haemost. 2008; 99: 602-608.
9. Rittersma SZ, van der Wal AC, Koch KT, et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005; 111: 1160-1165. (Pubitemid 40365478)
10. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999; 82: 265-268. (Pubitemid 29429594)
11. Holmes DR Jr, Kereiakes DJ, Kleiman NS, et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009; 54: 95-109.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
13. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353: 2373-2383. (Pubitemid 41713749)
14. Ferroni P, Martini F, Cardarello CM, et al. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation. 2003; 108: 1673-1675. (Pubitemid 37243651)
15. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010; 103: 71-82.
16. Dieker HJ, French JK, Joziasse IC, et al. Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction. Am Heart J. 2007; 153: 66.e1-66.e8.
17. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.
18. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26: 2787-2792.
19. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-325.
20. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30: 2311-2316.
21. Lonn E, Bosch J, Yusuf S, et al.; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293: 1338-1347. (Pubitemid 40381486)
22. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002; 105: 2107-2111. (Pubitemid 34465275)
23. Tardif JC, McMurray JJ, Klug E, et al.; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371: 1761-1768. (Pubitemid 351697951)
24. Serruys PW, García-García HM, Buszman P, et al.; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008; 118: 1172-1182.
25. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508-519. (Pubitemid 43980523)
26. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010; 134: 33-46.
27. Hansson GK, Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol. 2009; 31: 95-101.
28. Hermansson A, Ketelhuth DF, Strodthoff D, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010; 207: 1081-1093.
29. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006; 12: 178-180. (Pubitemid 43214743)
30. Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis? Curr Opin Lipidol. 2010; 21: 404-408.
31. Bentzon JF, Falk E. Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol. 2010; 21: 434-440.
32. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007; 110: 2983-2990. (Pubitemid 350006952)
33. Raes G, Van den Bergh R, De Baetselier P, et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol. 2005; 174: 6561-6562. (Pubitemid 40705613)
34. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
35. Libby P, Ridker PM. Inflammation and atherothrombosis: from population biology and bench research to clinical practice. J Am Coll Cardiol. 2006; 48: A33-A46. (Pubitemid 44648648)
36. Szczeklik W, Morawski W, Sanak M, et al. A single dose of aprotinin prevents platelet hyporeactivity after coronary artery bypass graft surgery. Pol Arch Med Wewn. 2010; 120: 321-327.
37. Sliz D, Mamcarz A, Filipiak KJ, et al. 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol Arch Med Wewn. 2010; 120: 328-333.
38. Wrigley BJ, Tapp LD, Shantsila E, Lip GY. Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting. Pol Arch Med Wewn. 2010; 120: 290-293.